Skip to main content
. Author manuscript; available in PMC: 2022 May 17.
Published in final edited form as: Leukemia. 2019 Dec 17;34(6):1524–1539. doi: 10.1038/s41375-019-0683-6

Figure 4: OT-82 reduces NAD+, ATP levels and serum visfatin levels and inhibits PARP-1 in ALL PDXs in vivo.

Figure 4:

(A) Each dot point represents the mean NAD+ luminescence per million spleen mononuclear cells for one PDX (n=8 PDX, n=2 mice for each PDX) or the mean ATP concentration per million cells for one PDX (n=8, minimum 2 mice for each PDX). Mean NAD+ luminescence/million cells values or mean ATP levels/million cells between treatment groups were compared by Welch’s t-test. (B) Immunoblotting of spleen mononuclear cells from PDXs treated with OT-82 (+) or vehicle (−) for 3 consecutive days. (C) Mean serum levels of visfatin as measured in PDX mice treated with OT-82 or vehicle on 3 consecutive days for minimum 2 mice per condition. Mean serum visfatin levels between OT-82 and vehicle-treated mice were compared by t-tests. Spleen mononuclear cells and serum were harvested 4h after final administration of a 3-day treatment course with daily injections of vehicle or 40 mg/kg OT-82. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.